Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
about
HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expressionInhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymeraseCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyDevelopment of a macrophage-based nanoparticle platform for antiretroviral drug delivery.NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapyComparative manufacture and cell-based delivery of antiretroviral nanoformulations.HIV-1 antiretroviral drug therapy.Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacityEtravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class.Macrophage polarization and HIV-1 infection.Targeting human immunodeficiency virus type 1 assembly, maturation and budding.HIV-1 persistent viremia is frequently followed by episodes of low-level viremia.Synthesis of prodrug-type anti-HIV agents conjugating a REVERSE transcriptase inhibitor to a HIV-1 integrase inhibitor by a spontaneously cleavable linker.Early initiation of antiretroviral treatment postSIV infection does not resolve lymphoid tissue activation.Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.Synthesis and anti-HIV evaluation of hybrid-type prodrugs conjugating HIV integrase inhibitors with d4t by self-cleavable spacers containing an amino acid residue.
P2860
Q21245193-835A18C5-E9C9-420F-8223-B8E1A06CAA7CQ28476610-7ADFC418-AE66-4463-832F-235533A60C84Q28551873-52E1FF24-D0E3-43F4-AEDC-5CC0712B74F1Q30479638-F5488EC4-7B38-4165-9D4C-987BCF291DA6Q30493643-98694222-6E89-46A3-BCEA-A6CC57002AB0Q34102337-2095956C-5D97-40D9-9D6F-1A96B873BD9DQ35139258-29618C3F-6F6E-4AF9-B9A1-39B6243C3F44Q35677168-977CDC2F-F198-464E-BEA0-8E7485A537FBQ35853012-AE1C94FC-1239-45CE-9E2F-35567992FA08Q36583732-E3F7570F-1709-438A-A5A8-2EE0967A094DQ36875347-7BA8AE0A-8B97-4189-8B56-F3438FF9659BQ37621172-05FB52F3-06E4-443A-966C-E680A6299D18Q37665065-9785B233-544A-40CF-8B29-6F6731B02EECQ37928913-60A65621-20B2-4DFC-B22C-C7AF65390DB5Q38951030-464B0482-969C-483A-94E1-9526B8ABD126Q40045544-98AEEC42-1B79-4617-A946-02164D50C16BQ40129327-BC3E9B8C-D166-4742-84C2-738ACF2F0D6BQ43011767-3F769376-35D6-4E92-98C3-1DE4FB9B8505Q46884382-C9BB0E17-BE5B-4671-A074-50A9F4542037
P2860
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
@ast
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
@en
type
label
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
@ast
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
@en
prefLabel
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
@ast
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
@en
P356
P1476
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
@en
P2093
Miranda Shehu-Xhilaga
Suzanne M Crowe
P304
P356
10.2174/0929867054367211
P577
2005-01-01T00:00:00Z